Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia's image recognition models also available on the PathPresenter platform

Aiforia Technologies

Translation: Original published in Finnish on 3/21/2025 at 4:53 pm EET.

PathPresenter is developing a workflow system for pathologists that integrates models from multiple image analysis solution providers (such as Aiforia). According to the press release, Aiforia's models will be made widely available on the PathPresenter platform. 

Earlier on Friday, Aiforia announced a very similar partnership with Techcyte, and we detailed the impact of such partnerships on the company's investment story in our comment at the time. These partnerships will, in principle, promote market formation and support the strong revenue growth we forecast for Aiforia, although there are nuances to the matter. Our more detailed commentary on the previous partnership press release can be found here. 

Aiforia Technologies

3.99EUR2025-03-21 18:00
4.40EURTarget price
Accumulate
Recommendation updated:10/03

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures10/03

202425e26e
202425e26e
Revenue2.94.77.6
growth-%18.9 %65.7 %60.0 %
EBIT (adj.)-12.2-11.9-12.0
EBIT-% (adj.)-427.8 %-252.9 %-158.1 %
EPS (adj.)-0.41-0.36-0.36
Dividend0.000.000.00
Dividend %
P/E (adj.)---
EV/EBITDA---
Showing sentiment questions page 1 out of 4

Questionnaire about Aiforia Technologies

The company is a good long-term investment

DisagreeAgree

The company has strong competitive advantages

DisagreeAgree

The company's management is reliable

DisagreeAgree
Very long text with the purpose to strech the component dynamically in all cases without unnecessary css declarations.
Please answer all the questions marked with *
1 / 4
Investor sentiment tool is provided by Inderes
Forum discussions
Aiforia is a company that has generated considerable discussion among investors. While some believe in its significant growth potential, the...
4/24/2025, 9:57 PM
by börsen84
0
Det strategiska partnerskapet integrerar Aiforias bildigenkänningsmodeller i Techcytes digitala plattform för patologilaboratorier, med start...
3/21/2025, 4:41 PM
by börsen84
0
Aiforia har ingått ett partnerskap med det kanadensiska företaget Quorum Technologies, som kommer att integrera Aiforias lösning och stödja ...
3/18/2025, 11:00 PM
by börsen84
0
Aiforia har valts som partner av hälsomyndigheterna på Sardinien för kliniska patologiska bildlösningar. Samarbetet omfattar analys av biopsier...
3/8/2025, 12:13 AM
by börsen84
0
Aiforia har fått CE-certifikat enligt den nya EU-förordningen (IVDR) och har lanserat tre nya AI-modeller. Detta möjliggör expansion inom kliniska...
2/23/2025, 10:18 PM
by börsen84
0
Here are analysts’ thoughts on this rather significant piece of news. Inderes Aiforia selected as partner for major regional health region in...
1/27/2025, 4:00 PM
by börsen84
1
Här är en video där Aiforias verkställande direktör berättar om företaget som en investeringsmöjlighet. Inderes Aiforia as an Investment | Life...
12/4/2024, 10:54 AM
by börsen84
0
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.